Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Open-label Substudy of Daily Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative Chronic Hepatitis B Co-infected With Hepatitis Delta

Trial Profile

Randomized Open-label Substudy of Daily Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative Chronic Hepatitis B Co-infected With Hepatitis Delta

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Apr 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bulevirtide (Primary) ; Peginterferon alfa
  • Indications Hepatitis B; Hepatitis D
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Hepatera
  • Most Recent Events

    • 16 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 15 Nov 2016 Final results presented at The Liver Meeting 2016: 67th Annual Meeting of the American Association for the Study of Liver Diseases
    • 27 Apr 2016 Interim results published in the Journal of Hepatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top